<![CDATA[20 On the Upswing: A Retrospective Cohort Study Evaluating Neoadjuvant Chemotherapy Response in Metaplastic Breast Cancer Patients]]>

Data ReadoutpositivepembrolizumabPositive

AI Analysis

Summary

A retrospective cohort study of 21 metaplastic breast cancer patients showed 48% achieved pathological complete response with neoadjuvant chemotherapy including pembrolizumab, with all responders disease-free at follow-up, suggesting improved outcomes in this chemoresistant subtype.

Clinical Trial Data

Primary Endpoint

Met

Patients

Outcome Details

48% pathological complete response (pCR) rate in metaplastic breast cancer patients receiving neoadjuvant chemotherapy with pembrolizumab, exceeding prior estimates

Importance:5/10

Sentiment:

0.70

oncologybreast cancerneoadjuvant chemotherapyimmunotherapymetaplastic breast cancerpathological complete response

Related Companies

$MRK

Read the original article

Published by Cancer Network on July 7, 2026 10:30 PM

Read Original